Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free MRKR Stock Alerts

Marker Therapeutics (MRKR) Financials

Marker Therapeutics logo
$1.34 -0.07 (-4.96%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$1.34 0.00 (0.00%)
As of 07/16/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Marker Therapeutics

Annual Income Statements for Marker Therapeutics

This table shows Marker Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -30 0.00 0.00 -11 -21 -29 -42 -30 -8.24 -11 -12
Consolidated Net Income / (Loss)		 -31 0.00 0.00 -11 -21 -29 -42 -30 -8.24 -11 -12
Net Income / (Loss) Continuing Operations		 -30 0.00 0.00 -11 -21 -29 -42 -20 -14 -11 -12
Total Pre-Tax Income 		-30 0.00 0.00 -11 -21 -29 -42 -20 -14 -11 -12
Total Operating Income		 -3.37 0.00 0.00 -11 -23 -29 -39 -20 -15 -11 -13
Total Gross Profit		 0.00 0.00 0.00 0.18 0.21 0.47 1.24 3.51 3.31 6.59 3.55
Total Revenue		 0.00 0.00 0.00 0.18 0.21 0.47 1.24 3.51 3.31 6.59 3.55
Operating Revenue		 - - - 0.18 0.21 0.47 1.24 3.51 3.31 6.59 3.55
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.37 0.00 0.00 12 23 29 41 23 18 18 16
Selling, General & Admin Expense		 3.18 - - 6.41 9.98 10 13 11 7.48 4.24 4.18
Research & Development Expense		 0.19 - - 5.25 13 19 28 12 10 13 12
Other Special Charges / (Income)		 - - - - - - - - - 0.00 0.45
Total Other Income / (Expense), net		 -27 0.00 0.00 0.50 1.10 0.18 -2.40 0.02 0.54 0.44 0.71
Interest & Investment Income		 - - - 0.00 1.08 0.15 0.01 0.25 0.54 0.44 0.59
Other Income / (Expense), net		 0.00 - - 0.01 0.02 0.03 -2.41 -0.23 - 0.00 0.12
Income Tax Expense		 - - - - - - - 0.00 0.00 0.05 -0.02
Basic Earnings per Share		 ($2.00) ($9.30) ($0.36) ($1.16) ($0.47) ($0.61) ($5.47) ($3.58) ($0.94) ($1.19) ($0.79)
Weighted Average Basic Shares Outstanding		 15.47M 3.66M 6.89M 9.45M 45.59M 47.04M 7.65M 8.35M 8.81M 8.98M 15.31M
Diluted Earnings per Share		 ($2.00) ($9.30) ($0.72) ($1.16) ($0.47) ($0.61) ($5.47) ($3.58) ($0.94) ($1.19) ($0.79)
Weighted Average Diluted Shares Outstanding		 15.47M 3.66M 7.42M 9.45M 45.59M 47.04M 7.65M 8.35M 8.81M 8.98M 15.31M
Weighted Average Basic & Diluted Shares Outstanding		 15.47M 43.95M 8.44M 9.45M 45.59M 47.04M 83.08M 8.80M 8.90M 10.71M 16.67M

Quarterly Income Statements for Marker Therapeutics

This table shows Marker Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.98 -2.80 -2.39 -2.19 -2.31 -3.84 -4.45 -4.02 -2.00 -1.70 -3.18
Consolidated Net Income / (Loss)		 -2.98 -2.80 -2.39 -2.19 -2.31 -3.84 -4.45 -4.02 -2.00 -1.70 -3.18
Net Income / (Loss) Continuing Operations		 -2.98 -2.74 0.00 -2.19 -2.31 -6.23 -4.45 -4.02 -2.00 -6.15 -3.18
Total Pre-Tax Income 		-2.98 -2.74 -2.39 -2.19 -2.31 -3.79 -4.45 -4.13 -2.00 -6.05 -3.19
Total Operating Income		 -3.20 -2.94 -2.55 -2.31 -2.40 -3.86 -4.96 -4.26 -2.14 -1.88 -4.07
Total Gross Profit		 0.26 1.06 1.24 1.17 1.93 2.25 0.00 0.86 1.23 1.10 0.00
Total Revenue		 0.26 1.06 1.24 1.17 1.93 2.25 0.00 0.86 1.23 1.10 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 3.46 3.99 3.79 3.48 4.33 6.11 4.96 5.12 3.37 2.99 4.07
Selling, General & Admin Expense		 1.41 1.38 1.22 1.14 0.85 1.03 1.37 0.95 1.02 0.85 1.23
Research & Development Expense		 2.04 2.62 2.58 2.34 3.47 5.09 3.14 4.18 2.35 2.14 2.84
Other Operating Expenses / (Income)		 - - - - - - 0.45 0.00 - - 0.00
Total Other Income / (Expense), net		 0.22 0.20 0.16 0.12 0.09 0.07 0.51 0.13 0.14 0.28 0.88
Interest & Investment Income		 0.22 0.20 0.16 0.12 0.09 0.07 0.16 0.13 0.14 0.17 0.13
Other Income / (Expense), net		 - - - - - - 0.35 - - - 0.75
Other Gains / (Losses), net		 - - - 0.00 0.00 - 0.00 0.12 0.00 - 0.01
Basic Earnings per Share		 ($0.34) ($0.32) ($0.27) ($0.25) ($0.26) ($0.43) ($0.40) ($0.29) ($0.12) $0.02 ($0.16)
Weighted Average Basic Shares Outstanding		 8.83M 8.81M 8.90M 8.92M 8.92M 8.98M 11.11M 13.96M 16.76M 15.31M 19.31M
Diluted Earnings per Share		 ($0.34) ($0.32) ($0.27) ($0.25) ($0.26) ($0.43) ($0.40) ($0.29) ($0.12) $0.02 ($0.16)
Weighted Average Diluted Shares Outstanding		 8.83M 8.81M 8.90M 8.92M 8.92M 8.98M 11.11M 13.96M 16.76M 15.31M 19.31M
Weighted Average Basic & Diluted Shares Outstanding		 8.89M 8.90M 8.92M 8.92M 8.92M 10.71M 11.31M 12.94M 16.67M 16.67M 16.67M

Annual Cash Flow Statements for Marker Therapeutics

This table details how cash moves in and out of Marker Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.09 6.43 1.27 -2.72 -18 -23 22 -32 3.33 4.08 -2.15
Net Cash From Operating Activities		 -2.19 -4.34 -6.51 -8.44 -18 -20 -27 -27 -16 -11 -12
Net Cash From Continuing Operating Activities		 -1.29 -4.34 -6.51 -8.44 -18 -20 -27 -22 -10 -11 -12
Net Income / (Loss) Continuing Operations		 -31 -34 -2.46 -11 -21 -29 -42 -20 -14 -11 -12
Consolidated Net Income / (Loss)		 -31 -34 -2.46 -11 -21 -29 -42 -30 -8.24 -11 -12
Non-Cash Adjustments To Reconcile Net Income		 29 1.74 1.63 2.25 5.17 5.23 5.96 3.03 0.86 0.75 0.36
Changes in Operating Assets and Liabilities, net		 0.31 28 -5.68 0.30 -2.31 2.37 5.47 -4.76 2.85 -0.93 -0.21
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 -0.37 -9.25 -3.13 -4.95 19 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 -0.37 -9.25 -3.13 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 2.28 11 7.78 5.72 0.82 6.74 53 0.20 1.11 15 9.86
Net Cash From Continuing Financing Activities		 2.28 11 7.78 5.72 0.82 6.74 53 0.20 1.11 15 9.86
Issuance of Common Equity		 1.88 2.46 2.33 5.41 0.00 6.19 53 0.20 1.01 15 9.86
Other Financing Activities, net		 - 8.45 5.50 0.62 0.82 0.55 0.00 0.00 0.09 0.06 0.00

Quarterly Cash Flow Statements for Marker Therapeutics

This table details how cash moves in and out of Marker Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.65 -2.36 -3.79 -3.52 1.20 10 -5.50 -1.88 7.13 -1.90 -1.40
Net Cash From Operating Activities		 -1.13 -2.37 -3.84 -3.57 1.20 -4.70 -5.50 -1.88 -2.74 -1.90 -1.40
Net Cash From Continuing Operating Activities		 -0.87 -2.30 -3.84 -3.57 1.20 -4.70 -5.50 -1.88 -2.74 -1.90 -1.40
Net Income / (Loss) Continuing Operations		 -2.98 -2.74 -2.39 -2.19 -2.31 -3.84 -4.45 -4.02 -2.00 -1.70 -3.18
Consolidated Net Income / (Loss)		 -2.98 -2.80 -2.39 -2.19 -2.31 -3.84 -4.45 -4.02 -2.00 -1.70 -3.18
Non-Cash Adjustments To Reconcile Net Income		 0.18 0.14 0.08 -0.33 0.27 0.73 0.02 -0.78 0.19 0.58 0.42
Changes in Operating Assets and Liabilities, net		 1.94 0.29 -1.52 -1.04 3.23 -1.60 -1.08 2.92 -0.92 -0.78 1.36
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 0.48 0.01 0.05 0.04 0.00 15 0.00 0.00 9.86 - 0.00
Net Cash From Continuing Financing Activities		 0.48 0.01 0.05 0.04 0.00 15 0.00 0.00 9.86 - 0.00
Other Financing Activities, net		 0.08 0.01 0.05 0.01 0.00 0.00 0.00 0.00 - - 0.00

Annual Balance Sheets for Marker Therapeutics

This table presents Marker Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.22 6.65 7.92 5.18 46 46 68 34 17 22 19
Total Current Assets		 0.22 6.65 7.92 5.18 45 24 46 17 17 22 19
Cash & Equivalents		 0.14 6.58 7.85 5.13 44 21 42 12 15 19 16
Restricted Cash		 - - - - - - 1.15 - - 0.00 0.97
Accounts Receivable		 - - - - 0.00 1.00 0.00 2.40 1.03 2.35 1.37
Prepaid Expenses		 0.08 0.07 0.07 0.05 1.53 2.06 2.48 1.85 0.99 0.48 0.66
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.87 21 22 18 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 0.22 6.65 7.92 5.18 46 46 68 34 17 22 19
Total Liabilities		 1.25 28 1.74 1.52 2.27 18 24 15 3.07 3.46 2.27
Total Current Liabilities		 1.25 28 1.74 1.52 1.99 6.40 13 7.78 3.07 3.46 2.27
Accounts Payable		 0.69 0.97 1.22 1.51 1.76 6.01 11 2.52 1.75 1.75 1.30
Current Deferred Revenue		 - - - - - - 1.15 - - 0.00 0.97
Other Current Liabilities		 0.52 27 0.51 0.01 0.24 0.39 0.62 0.00 1.33 1.71 0.00
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.28 12 11 7.04 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 - - - - 0.28 12 11 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.02 -21 6.18 3.66 44 27 44 20 14 19 17
Total Preferred & Common Equity		 -1.02 -21 6.18 3.66 44 27 44 20 14 19 17
Preferred Stock		 - - - - 0.00 - - 0.00 0.00 0.00 0.00
Total Common Equity		 -1.02 -21 6.18 3.66 44 27 44 20 14 19 17
Common Stock		 85 112 152 161 372 384 442 448 450 466 476
Retained Earnings		 -86 -134 -146 -157 -328 -356 -398 -428 -436 -447 -459

Quarterly Balance Sheets for Marker Therapeutics

This table presents Marker Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 19 14 12 11 17 15 22 17
Total Current Assets		 19 14 12 11 17 15 22 17
Cash & Equivalents		 17 11 7.80 9.00 14 10 18 15
Restricted Cash		 - - - - - 1.35 1.35 0.72
Accounts Receivable		 0.08 1.85 2.49 0.74 2.46 1.67 1.67 1.38
Prepaid Expenses		 1.93 0.92 1.38 1.17 0.84 1.28 1.13 0.42
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 19 14 12 11 17 15 22 17
Total Liabilities		 2.78 2.30 1.97 3.46 2.50 4.28 3.35 3.64
Total Current Liabilities		 2.78 2.30 1.97 3.46 2.50 4.28 3.35 3.64
Accounts Payable		 2.30 1.95 1.68 2.56 2.09 2.27 1.66 1.91
Current Deferred Revenue		 0.11 - - - - 1.35 1.35 0.72
Other Current Liabilities		 0.37 0.35 0.29 0.90 0.41 0.66 0.33 1.00
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 17 12 9.70 7.45 14 10 18 14
Total Preferred & Common Equity		 17 12 9.70 7.45 14 10 18 14
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 17 12 9.70 7.45 14 10 18 14
Common Stock		 450 450 451 451 466 466 476 476
Retained Earnings		 -433 -439 -441 -443 -451 -455 -457 -462

Annual Metrics And Ratios for Marker Therapeutics

This table displays calculated financial ratios and metrics derived from Marker Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 129,237,524.00 8,379,101.00 10,539,057.00 45,370,695.00 45,723,414.00 48,025,102.00 83,078,675.00 83,599,187.00 8,889,020.00 8,923,490.00 16,673,127.00
DEI Adjusted Shares Outstanding		 12,923,752.00 837,910.00 1,053,906.00 4,537,069.00 4,572,341.00 4,802,510.00 8,307,867.00 8,359,919.00 8,889,020.00 8,923,490.00 16,673,127.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -10.42 - -4.69 -5.98 -5.04 -3.58 -0.93 -1.20 -0.73
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 12.53% 0.00% 118.95% 166.01% 182.96% -5.76% 99.06% -46.19%
EBITDA Growth		 100.00% 0.00% 0.00% -1,191.66% 85.01% -24.99% -39.39% 48.29% 27.18% 23.75% -14.88%
EBIT Growth		 100.00% 0.00% 0.00% -1,191.66% 84.81% -28.18% -45.16% 52.19% 27.18% 23.75% -14.88%
NOPAT Growth		 100.00% 0.00% 0.00% -1,190.69% 89.36% -28.22% -36.67% 49.87% 26.32% 23.75% -15.94%
Net Income Growth		 100.00% 0.00% 0.00% -1,247.25% 0.00% -33.97% -45.89% 28.53% 72.48% -30.28% -13.35%
EPS Growth		 -365.00% 92.26% -61.11% -568.10% 0.00% -29.79% -45.89% 28.53% 73.74% -26.60% 33.61%
Operating Cash Flow Growth		 -98.59% -49.88% -29.64% -71.57% 0.00% -9.57% -36.16% 1.13% 39.05% 33.64% -10.12%
Free Cash Flow Firm Growth		 488.86% -198.03% 68.63% -1,161.61% 87.53% -41.79% 14.98% 31.79% 50.86% -10.65% -14.66%
Invested Capital Growth		 -2,355.35% 94.04% 11.46% -63.54% 107.58% 3,187.46% -91.85% 254.33% -161.21% 40.12% 61.20%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -47.05% 0.00% 0.00% 0.00% -12.08% 9.87% 22.15% -24.46%
EBITDA Q/Q Growth		 100.00% 0.00% 0.00% -616.84% 0.00% -4,120.08% -9.34% 34.68% -38.28% -9.06% 14.09%
EBIT Q/Q Growth		 100.00% 0.00% 0.00% -616.84% 0.00% 0.00% -9.58% 34.68% -38.28% -9.06% 14.09%
NOPAT Q/Q Growth		 100.00% 0.00% 0.00% -619.90% 0.00% 0.00% -3.29% 35.44% -38.28% -9.06% 13.30%
Net Income Q/Q Growth		 100.00% 0.00% 0.00% -813.44% 0.00% 0.00% -3.09% 16.48% 11.34% -10.67% 14.93%
EPS Q/Q Growth		 -314.78% 0.00% 0.00% -500.78% 0.00% 0.00% -3.09% 16.48% 10.48% -9.17% 7.06%
Operating Cash Flow Q/Q Growth		 -4.37% -16.10% -9.40% -34.13% 0.00% -4.94% 2.31% -5.67% 19.32% -27.24% 18.92%
Free Cash Flow Firm Q/Q Growth		 -12.12% 0.00% 0.00% 0.00% -511.33% -514.36% 17.09% 32.63% -255.06% -29.19% 17.47%
Invested Capital Q/Q Growth		 16.58% 0.00% 0.00% 33.14% 130.60% 64.57% -86.35% -61.77% -38.10% 59.10% 55.59%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -6,268.05% -71,949.49% -10,424.41% -5,951.16% -3,118.44% -569.91% -440.37% -168.69% -360.14%
Operating Margin		 0.00% 0.00% -6,271.05% -71,930.07% -10,567.28% -6,188.25% -3,179.32% -563.28% -440.37% -168.69% -363.45%
EBIT Margin		 0.00% 0.00% -6,268.05% -71,949.49% -10,558.84% -6,181.61% -3,373.14% -569.91% -440.37% -168.69% -360.14%
Profit (Net Income) Margin		 0.00% 0.00% -5,999.09% -71,826.32% -10,050.92% -6,149.74% -3,372.68% -851.87% -248.76% -162.82% -342.96%
Tax Burden Percent		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 151.35% 58.66% 100.47% 99.88%
Interest Burden Percent		 0.00% 0.00% 95.71% 99.83% 95.19% 99.48% 99.99% 98.76% 96.30% 96.07% 95.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -654.96% -852.86% -1,249.03% -3,041.67% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -628.95% -808.93% -1,196.63% -3,053.61% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 574.58% 735.44% 1,154.89% 2,992.72% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% -223.15% -469.72% -97.21% -80.37% -117.42% -94.14% -48.95% -65.81% -68.81%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -10,071.90% -843.15% -683.00% -1,360.99% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -175.16% -440.29% -97.11% -62.75% -73.64% -39.05% -56.57% -56.80% -62.16%
Return on Assets (ROA)		 0.00% 0.00% -167.64% -439.54% -92.44% -62.42% -73.63% -58.37% -31.96% -54.82% -59.20%
Return on Common Equity (ROCE)		 0.00% 0.00% -223.15% -469.72% -97.21% -80.37% -117.42% -94.14% -48.95% -65.81% -68.81%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -300.21% -249.34% -48.60% -104.98% -95.21% -152.70% -58.61% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.00 0.00 -8.04 -148 -16 -20 -28 -14 -10 -7.78 -9.02
NOPAT Margin		 0.00% 0.00% -4,389.74% -71,930.07% -7,397.10% -4,331.77% -2,225.53% -394.29% -308.26% -118.08% -254.42%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% -45.41% 0.64% -10.71% -26.01% -43.93% -52.40% 11.95% -17.19% -17.33%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -72.63% -41.94% -53.72%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 3,502.67% 11,835.23% 4,679.87% 2,243.40% 1,040.89% 322.64% 225.78% 64.35% 117.99%
R&D to Revenue		 0.00% 0.00% 2,868.39% 60,194.84% 5,987.41% 4,044.85% 2,238.44% 340.64% 314.60% 204.33% 332.68%
Operating Expenses to Revenue		 0.00% 0.00% 6,371.05% 72,030.07% 10,667.28% 6,288.25% 3,279.32% 663.28% 540.37% 268.69% 463.45%
Earnings before Interest and Taxes (EBIT)		 0.00 0.00 -11 -148 -23 -29 -42 -20 -15 -11 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.00 0.00 -11 -148 -22 -28 -39 -20 -15 -11 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 5.26 11.29 1.79 2.99 2.55 1.79 1.13 3.48 1.50 1.48
Price to Tangible Book Value (P/TBV)		 0.00 5.26 11.29 1.79 2.99 2.55 1.79 1.13 3.48 1.50 1.48
Price to Revenue (P/Rev)		 0.00 0.00 225.68 514.38 617.67 149.18 63.57 6.33 14.77 4.21 7.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% -139.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 481.58 8.06 72.59 6.04 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 197.66 214.63 411.74 103.44 28.54 2.97 10.20 1.30 2.20
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 3.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.30 0.95 -1.32 -1.06 -2.40 -0.91 -0.91 -0.97 -0.98 -1.05 -1.02
Leverage Ratio		 -0.31 -0.96 1.33 1.07 1.05 1.29 1.59 1.61 1.53 1.20 1.16
Compound Leverage Factor		 0.00 0.00 1.27 1.07 1.00 1.28 1.59 1.59 1.48 1.15 1.11
Debt to Total Capital		 -0.25% 0.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -0.25% 0.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.25% 99.92% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -29.67 -13.60 -32.69 9.06 24.40 -10.25 -7.65 -18.02 -27.75 -23.97 -28.12
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.24 4.56 3.40 22.11 22.83 3.81 3.56 2.14 5.57 6.36 8.39
Quick Ratio		 0.23 4.52 3.37 22.02 22.03 3.49 3.28 1.82 5.25 6.22 7.67
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 27 -26 -8.23 -147 -18 -26 -22 -15 -7.42 -8.21 -9.41
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -9,805.72% -4,876.03% -585.34% -1,735.18% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.03 0.01 0.01 0.01 0.02 0.07 0.13 0.34 0.17
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 2.48 2.93 1.93 3.91 1.91
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 147.09 124.78 189.04 93.44 191.22
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 147.09 124.78 189.04 93.44 191.22
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -28 -1.66 -1.47 -2.41 0.18 5.99 0.49 1.73 -1.06 -0.63 -0.25
Invested Capital Turnover		 0.00 0.00 -0.12 -0.11 -0.19 0.15 0.38 3.17 9.87 -7.79 -8.06
Increase / (Decrease) in Invested Capital		 -27 26 0.19 -0.93 2.59 5.81 -5.50 1.24 -2.79 0.42 0.39
Enterprise Value (EV)		 101 25 36 44 88 48 35 10 34 8.56 7.80
Market Capitalization		 108 33 41 106 132 70 79 22 49 28 25
Book Value per Share		 ($0.33) $0.74 $0.35 $3.11 $0.96 $0.57 $0.53 $0.23 $1.58 $2.08 $1.01
Tangible Book Value per Share		 ($0.33) $0.74 $0.35 $3.11 $0.96 $0.57 $0.53 $0.23 $1.58 $2.08 $1.01
Total Capital		 -21 6.19 3.66 59 44 27 44 20 14 19 17
Total Debt		 0.05 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -6.52 -7.85 -5.13 -62 -44 -21 -43 -12 -15 -19 -17
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.15 0.37 3.42 1.57 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -28 -1.66 -1.47 -2.55 -0.41 -3.34 -10 -2.94 -1.06 -0.63 -0.25
Debt-free Net Working Capital (DFNWC)		 -21 6.19 3.66 59 43 18 33 8.84 14 19 17
Net Working Capital (NWC)		 -21 6.18 3.66 59 43 18 33 8.84 14 19 17
Net Nonoperating Expense (NNE)		 0.00 0.00 2.95 -0.21 5.66 8.49 14 16 -1.97 2.95 3.14
Net Nonoperating Obligations (NNO)		 -6.52 -7.85 -5.13 -62 -44 -21 -43 -18 -15 -19 -17
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.29 1.08 3.16 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -803.63% -1,239.69% -192.40% -716.24% -838.90% -83.81% -31.98% -9.62% -6.94%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,998.28% 28,735.34% 20,401.03% 3,858.11% 2,664.12% 251.53% 424.40% 281.57% 473.59%
Net Working Capital to Revenue		 0.00% 0.00% 1,998.28% 28,735.34% 20,401.03% 3,858.11% 2,664.12% 251.53% 424.40% 281.57% 473.59%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($7.80) ($3.60) ($11.60) ($7.75) $0.00 ($6.10) ($5.50) ($3.58) ($0.94) ($1.19) ($0.79)
Adjusted Weighted Average Basic Shares Outstanding		 4.39M 688.99K 945.35K 19.09M 0.00 5.07M 7.65M 8.35M 8.81M 8.98M 15.31M
Adjusted Diluted Earnings per Share		 ($7.80) ($7.20) ($11.60) ($7.75) $0.00 ($6.10) ($5.50) ($3.58) ($0.94) ($1.19) ($0.79)
Adjusted Weighted Average Diluted Shares Outstanding		 4.39M 742.10K 945.35K 19.09M 0.00 5.07M 7.65M 8.35M 8.81M 8.98M 15.31M
Adjusted Basic & Diluted Earnings per Share		 ($7.80) $0.00 ($11.60) ($7.75) $0.00 ($6.10) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.39M 843.92K 1.06M 19.09M 0.00 4.70M 8.31M 8.80M 8.90M 10.71M 16.67M
Normalized Net Operating Profit after Tax (NOPAT)		 0.00 0.00 -8.04 -104 -16 -20 -28 -14 -10 -7.78 -8.71
Normalized NOPAT Margin		 0.00% 0.00% -4,389.74% -50,351.05% -7,397.10% -4,331.77% -2,225.53% -394.29% -308.26% -118.08% -245.47%
Pre Tax Income Margin		 0.00% 0.00% -5,999.09% -71,826.32% -10,050.92% -6,149.74% -3,372.68% -562.85% -424.09% -162.06% -343.39%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -2.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Marker Therapeutics

This table displays calculated financial ratios and metrics derived from Marker Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 8,809,260.00 8,889,020.00 8,902,897.00 8,919,095.00 8,922,695.00 8,923,490.00 10,709,005.00 11,314,835.00 12,938,910.00 16,673,127.00 16,673,127.00
DEI Adjusted Shares Outstanding		 8,809,260.00 8,889,020.00 8,902,897.00 8,919,095.00 8,922,695.00 8,923,490.00 10,709,005.00 11,314,835.00 12,938,910.00 16,673,127.00 16,673,127.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.34 -0.32 -0.27 -0.25 -0.26 -0.43 -0.42 -0.35 -0.15 -0.10 -0.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -74.23% 39.17% 0.79% 53.31% 647.66% 113.13% -100.00% -26.35% -35.99% -51.00% 0.00%
EBITDA Growth		 45.08% -367.38% 40.85% 44.17% 25.01% -31.44% -80.80% -84.61% 10.97% 51.21% 27.94%
EBIT Growth		 45.08% -367.38% 40.85% 44.17% 25.01% -31.44% -80.80% -84.61% 10.97% 51.21% 27.94%
NOPAT Growth		 45.08% -287.17% 40.85% 44.17% 25.01% -31.44% -94.50% -84.61% 10.97% 51.21% 17.86%
Net Income Growth		 56.91% 27.31% 51.83% -187.16% 22.59% -36.91% -85.81% -83.14% 13.41% 55.62% 28.49%
EPS Growth		 59.04% 30.43% 52.63% -186.21% 23.53% -34.38% -48.15% -16.00% 53.85% 104.65% 60.00%
Operating Cash Flow Growth		 85.25% 62.45% 34.83% 49.44% 206.21% -98.65% -43.33% 47.35% -328.47% 59.60% 74.47%
Free Cash Flow Firm Growth		 160.71% 612.06% 234.92% -25.92% -129.38% -527.01% -160.74% 110.41% -177.90% 45.43% 94.50%
Invested Capital Growth		 -116.94% -161.21% -94.54% 62.18% -102.15% 40.12% 71.83% -169.63% 64.26% 61.20% -330.72%
Revenue Q/Q Growth		 -66.22% 310.14% 17.75% -6.01% 64.72% 16.91% -100.00% 146.68% 43.17% -10.50% -100.00%
EBITDA Q/Q Growth		 22.59% 8.20% 13.23% 9.45% -3.98% -60.90% -19.35% 7.54% 49.85% 11.83% -76.27%
EBIT Q/Q Growth		 22.59% 8.20% 13.23% 9.45% -3.98% -60.90% -19.35% 7.54% 49.85% 11.83% -76.27%
NOPAT Q/Q Growth		 22.59% 8.20% 13.23% 9.45% -3.98% -60.90% -28.39% 7.54% 49.85% 11.83% -116.17%
Net Income Q/Q Growth		 -218.53% 6.00% 14.64% 8.36% -5.27% -66.26% -15.86% 9.69% 50.23% 14.78% -86.66%
EPS Q/Q Growth		 -217.24% 5.88% 15.63% 7.41% -4.00% -65.38% 6.98% 27.50% 58.62% 116.67% -900.00%
Operating Cash Flow Q/Q Growth		 84.02% -109.99% -62.07% 7.02% 133.57% -492.75% -16.94% 65.85% -45.65% 30.55% 26.10%
Free Cash Flow Firm Q/Q Growth		 263.90% -76.00% 755.01% -137.44% 61.76% -248.85% -21.63% 106.86% -1,120.66% 31.50% 87.73%
Invested Capital Q/Q Growth		 -165.37% -38.10% 143.89% 309.27% -181.49% 59.10% 225.97% -265.85% 58.17% 55.59% -648.96%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -1,242.22% -278.06% -204.89% -197.40% -124.60% -171.48% 0.00% -494.79% -173.30% -170.74% 0.00%
Operating Margin		 -1,242.22% -278.06% -204.89% -197.40% -124.60% -171.48% 0.00% -494.79% -173.30% -170.74% 0.00%
EBIT Margin		 -1,242.22% -278.06% -204.89% -197.40% -124.60% -171.48% 0.00% -494.79% -173.30% -170.74% 0.00%
Profit (Net Income) Margin		 -1,157.57% -265.31% -192.34% -187.53% -119.84% -170.43% 0.00% -466.28% -162.11% -154.35% 0.00%
Tax Burden Percent		 100.00% 102.43% 100.00% 100.00% 100.00% 101.32% 100.00% 97.16% 100.00% 28.17% 99.73%
Interest Burden Percent		 93.18% 93.15% 93.87% 95.00% 96.18% 98.09% 96.47% 97.00% 93.54% 320.97% 96.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,394.49% -1,920.56% -106.12% -334.97% 0.00% 0.00% 0.00% -6,460.15% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,390.31% -1,916.03% -99.62% -330.47% 0.00% 0.00% 0.00% -6,449.62% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 1,257.38% 1,877.82% 67.34% 295.11% 0.00% 0.00% 0.00% 6,265.09% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -137.11% -42.74% -38.78% -39.86% -80.28% -65.81% 0.00% -195.06% -110.67% -68.81% -77.04%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -20.66% -547.98% 0.00% 0.00% -1,551.74% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -123.55% -35.72% -32.38% -43.76% -44.24% -57.74% 0.00% -201.64% -49.85% -29.47% 0.00%
Return on Assets (ROA)		 -115.13% -34.08% -30.39% -41.57% -42.55% -57.38% 0.00% -190.02% -46.63% -26.64% 0.00%
Return on Common Equity (ROCE)		 -137.11% -42.74% -38.78% -39.86% -80.28% -65.81% 0.00% -195.06% -110.67% -68.81% -77.04%
Return on Equity Simple (ROE_SIMPLE)		 -55.61% 0.00% -48.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.24 -2.06 -1.78 -1.62 -1.68 -2.70 -3.47 -2.98 -1.50 -1.32 -2.85
NOPAT Margin		 -869.56% -194.64% -143.43% -138.18% -87.22% -120.04% 0.00% -346.35% -121.31% -119.52% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.17% -4.53% -6.50% -4.50% -4.75% -6.62% -7.80% -10.53% -3.60% -2.12% -2.24%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.63% -15.14% -16.65% -22.55% -14.56% -23.95% -28.43% -8.13% -7.85% -20.66%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 548.38% 130.33% 97.91% 97.66% 44.38% 45.61% 0.00% 109.75% 83.04% 76.72% 0.00%
R&D to Revenue		 793.84% 247.73% 206.98% 199.74% 180.23% 225.88% 0.00% 485.04% 190.26% 194.01% 0.00%
Operating Expenses to Revenue		 1,342.22% 378.06% 304.89% 297.40% 224.60% 271.48% 0.00% 594.79% 273.30% 270.74% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.20 -2.94 -2.55 -2.31 -2.40 -3.86 -4.61 -4.26 -2.14 -1.88 -3.32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.20 -2.94 -2.55 -2.31 -2.40 -3.86 -4.61 -4.26 -2.14 -1.88 -3.32
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.39 3.48 3.25 4.99 3.38 1.50 0.91 1.65 0.63 1.48 1.57
Price to Tangible Book Value (P/TBV)		 2.39 3.48 3.25 4.99 3.38 1.50 0.91 1.65 0.63 1.48 1.57
Price to Revenue (P/Rev)		 13.27 14.77 11.53 12.99 4.66 4.21 2.46 3.21 2.46 7.00 6.11
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 58.00 21.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 7.47 10.20 8.12 10.90 3.00 1.30 0.00 1.02 0.00 2.20 1.70
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.90 -0.98 -0.68 -0.89 -1.10 -1.05 -0.95 -0.97 -1.08 -1.02 -1.04
Leverage Ratio		 1.54 1.53 1.52 1.17 1.26 1.20 1.18 1.31 1.26 1.16 1.22
Compound Leverage Factor		 1.44 1.43 1.42 1.11 1.21 1.18 1.14 1.27 1.18 3.73 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -21.87 -25.51 -32.97 -37.47 -51.92 -22.88 -33.59 -40.49 -26.49 -26.24 -33.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.01 5.57 6.12 5.92 3.15 6.36 6.79 3.45 6.50 8.39 4.79
Quick Ratio		 6.32 5.25 5.72 5.22 2.82 6.22 6.46 2.84 5.75 7.67 4.48
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 3.05 0.73 6.26 -2.34 -0.90 -3.13 -3.80 0.24 -2.49 -1.71 -0.21
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.10 0.13 0.16 0.22 0.36 0.34 0.34 0.41 0.29 0.17 0.21
Accounts Receivable Turnover		 3.42 1.93 2.26 1.76 13.04 3.91 2.48 2.59 3.90 1.91 1.85
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 106.84 189.04 161.26 207.41 28.00 93.44 147.11 141.06 93.66 191.22 197.39
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 106.84 189.04 161.26 207.41 28.00 93.44 147.11 141.06 93.66 191.22 197.39
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.77 -1.06 0.46 1.90 -1.55 -0.63 0.80 -1.32 -0.55 -0.25 -1.84
Invested Capital Turnover		 1.60 9.87 0.74 2.42 -4.66 -7.79 8.46 18.65 -4.46 -8.06 -6.79
Increase / (Decrease) in Invested Capital		 -5.29 -2.79 -8.05 0.73 -0.78 0.42 0.33 -3.23 1.00 0.39 -2.64
Enterprise Value (EV)		 23 34 27 41 16 8.56 -0.52 5.50 -7.39 7.80 6.04
Market Capitalization		 40 49 38 48 25 28 13 17 12 25 22
Book Value per Share		 $1.90 $1.58 $1.32 $1.09 $0.83 $2.08 $1.62 $0.93 $1.42 $1.01 $0.83
Tangible Book Value per Share		 $1.90 $1.58 $1.32 $1.09 $0.83 $2.08 $1.62 $0.93 $1.42 $1.01 $0.83
Total Capital		 17 14 12 9.70 7.45 19 14 10 18 17 14
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -17 -15 -11 -7.80 -9.00 -19 -14 -12 -19 -17 -16
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.77 -1.06 0.46 1.90 -1.55 -0.63 0.80 -1.32 -0.55 -0.25 -1.84
Debt-free Net Working Capital (DFNWC)		 17 14 12 9.70 7.45 19 14 10 18 17 14
Net Working Capital (NWC)		 17 14 12 9.70 7.45 19 14 10 18 17 14
Net Nonoperating Expense (NNE)		 0.74 0.75 0.61 0.58 0.63 1.13 0.98 1.03 0.50 0.38 0.33
Net Nonoperating Obligations (NNO)		 -17 -15 -11 -7.80 -9.00 -19 -14 -12 -19 -17 -16
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -25.44% -31.98% 14.00% 51.04% -28.73% -9.62% 14.94% -24.58% -11.80% -6.94% -51.96%
Debt-free Net Working Capital to Revenue		 554.36% 424.40% 354.98% 260.31% 138.06% 281.57% 271.03% 194.70% 391.67% 473.59% 388.98%
Net Working Capital to Revenue		 554.36% 424.40% 354.98% 260.31% 138.06% 281.57% 271.03% 194.70% 391.67% 473.59% 388.98%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.34) ($0.32) ($0.27) ($0.25) ($0.26) ($0.43) ($0.40) ($0.29) ($0.12) $0.02 ($0.16)
Adjusted Weighted Average Basic Shares Outstanding		 8.83M 8.81M 8.90M 8.92M 8.92M 8.98M 11.11M 13.96M 16.76M 15.31M 19.31M
Adjusted Diluted Earnings per Share		 ($0.34) ($0.32) ($0.27) ($0.25) ($0.26) ($0.43) ($0.40) ($0.29) ($0.12) $0.02 ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 8.83M 8.81M 8.90M 8.92M 8.92M 8.98M 11.11M 13.96M 16.76M 15.31M 19.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.32) $0.00 $0.00 $0.00 ($0.43) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.89M 8.90M 8.92M 8.92M 8.92M 10.71M 11.31M 12.94M 16.67M 16.67M 16.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.24 -2.06 -1.78 -1.62 -1.68 -2.70 -3.47 -2.98 -1.50 -1.32 -2.85
Normalized NOPAT Margin		 -869.56% -194.64% -143.43% -138.18% -87.22% -120.04% 0.00% -346.35% -121.31% -119.52% 0.00%
Pre Tax Income Margin		 -1,157.57% -259.00% -192.34% -187.53% -119.84% -168.21% 0.00% -479.92% -162.11% -548.02% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Marker Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Marker Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

The last 5 years of Marker Therapeutics' net income performance:
  • 2021: -$41.88 million
  • 2022: -$29.93 million
  • 2023: -$8.24 million
  • 2024: -$10.73 million
  • 2025: -$12.16 million
Find out what analysts predict for Marker Therapeutics in the coming months.

Marker Therapeutics' total operating income in 2025 was -$12.89 million, based on the following breakdown:
  • Total Gross Profit: $3.55 million
  • Total Operating Expenses: $16.44 million

Over the last 10 years, Marker Therapeutics' total revenue changed from $0.00 in 2014 to $3.55 million in 2025, a change of 354,666,900.0%.

Marker Therapeutics' total liabilities were at $2.27 million at the end of 2025, a 34.4% decrease from 2024, and a 82.2% increase since 2014.

In the past 10 years, Marker Therapeutics' cash and equivalents has ranged from $141.94 thousand in 2014 to $43.90 million in 2019, and is currently $16.07 million as of their latest financial filing in 2025.

Over the last 10 years, Marker Therapeutics' book value per share changed from -0.33 in 2015 to 1.01 in 2025, a change of -404.7%.


Related Companies

Financial statements for NASDAQ:MRKR last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel